colorectal cancer
Conditions
Interventions
Oliceridine Group (Group O):Patient-controlled intravenous analgesia (PCIA) with oliceridine alone. The PCIA solution contains oliceridine 20 mg diluted in normal saline to 100 mL. The pump is set wit
Esketamine Group (Group E):Patient-controlled intravenous analgesia (PCIA) with esketamine alone. The PCIA solution contains esketamine 100 mg diluted in normal saline to 100 mL. The pump is set with
Oliceridine + Esketamine Combination Group (Group OE):Patient-controlled intravenous analgesia (PCIA) with a combination of oliceridine and esketamine. The PCIA solution contains oliceridine 20 mg and
Sponsors
Henan University Huaihe Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 65–80 years; 2. Scheduled for elective laparoscopic radical resection of colorectal cancer; 3. ASA physical status II–III; 4. Informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. History of drug allergy; 2. Severe hepatic or renal insufficiency; 3. History of chronic pain or long-term opioid use; 4. Severe psychiatric or cognitive disorders; 5. History of drug or alcohol abuse; 6. Conversion to open surgery or occurrence of severe intraoperative complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative active pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total consumption of oliceridine within 48 hours post-operation;Postoperative adverse reaction incidence rate;Postoperative Recovery Quality Score;Number of compressions of analgesic pump;First anal exhaust time after surgery;Post hospitalization duration; | — |
Countries
China
Contacts
Public ContactLimin Liang
Henan University Huaihe Hospital
Outcome results
None listed